Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers

Liang Li, Brooke L. Fridley, Krishna Kalari et al. · 2009

Read Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers by Liang Li, Brooke L. Fridley, Krishna Kalari et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0007765.txt.

Description

Liang Li and co-authors published a study in PLOS ONE in 2009. It searches the genome for markers that predict response to two cancer drugs. The drugs are gemcitabine and AraC, both copies of a DNA building block. Patients vary widely in how they respond to chemotherapy.

The team ran a genome-wide association study using cell line data. They linked DNA variants to how strongly the drugs worked. Such markers are called pharmacogenomic biomarkers. If they hold up in patients, doctors could test DNA before choosing a dose. That promises stronger effects with fewer side effects.

Catalog record

CREATORLiang Li, Brooke L. Fridley, Krishna Kalari et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE79 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0007765

Browse the full library · About the Tower of Babel